Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

167242

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	23andMe
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what contact the Medicines and Healthcare Products Regulatory Agency had with the US Food and Drug Administration prior to its approval of 23andMe.
tabling member printed	Lord Mendelsohn
uin	HL3343
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>Products used in direct-to-consumer testing services providing health-related information are regulated as <em>in vitro</em> diagnostic medical devices and are subject to European Union legislation that sets out minimum standards of safety and quality. The testing service itself is not subject to this legislation, only the products.</p><p> </p><p> </p><p> </p><p>Manufacturers of <em>in vitro</em> diagnostic medical devices are required to register with the competent authority in the country where they are placing the device on the market. In the United Kingdom this is the Medicines and Healthcare products Regulatory Agency (MHRA). In this registration a manufacturer declares that their devices are safe and meet all of the relevant requirements of the legislation including having evidence to support their performance claims. For some higher risk devices a manufacturer has to have its product checked before it is placed on the market. Such checks are undertaken by third-party conformity assessment bodies called notified bodies.</p><p> </p><p> </p><p> </p><p>The role of the MHRA is to ensure that all medical devices placed on the UK market are compliant with the relevant legislation and to enforce this legislation on behalf of the Secretary of State. The MHRA fulfils this role by monitoring notified bodies (for higher risk devices) and operating the UK medical device vigilance system, which involves assessing and responding to safety concerns involving devices.</p><p> </p><p> </p><p> </p><p>The MHRA does not have a role in assessing the additional costs or benefits of devices to the National Health Service and so has not done so in the case of the service offered by 23andMe.</p><p> </p><p> </p><p> </p><p>Furthermore, under existing EU legislation, testing services are regulated in the country where the test is being performed. The tests offered by 23andMe are performed in laboratories that are based in the United States of America and as such are covered by US legislation.</p><p> </p><p> </p><p> </p><p>The Government has advised that no test will be 100% reliable, that 23andMe should be used with caution and that the information provided by 23andMe should not lead consumers to make any changes of medical significance, such as changes to medication, without first consulting their healthcare professional. If consumers need more information about the conditions listed in their results then they can visit the NHS Choices website for more information.</p><p> </p><p> </p><p> </p><p>The MHRA discussed the 23andMe Personal Genome Service with the US Food and Drug Administration (FDA) and shared information under the confidentiality commitment that is in place between the two agencies.</p><p> </p><p> </p><p> </p><p>The MHRA also held discussions with 23andMe prior to them launching their product in the UK. In those discussions, 23andMe explained that the product being offered in the UK is different to their US product in that many of the drug responses, inherited conditions and genetic health risks that were of concern to the FDA have been removed. 23andMe also presented results of surveys with UK-based consumers of their existing service that demonstrated that 4% of people had a specific conversation with their general practitioner (GP) as a result of their test results but it is not known how many GP visits led to National Health Service treatment.</p><p> </p><p> </p><p> </p><p>In the context of those discussions, the MHRA also agreed with 23andMe that they would take part in an enhanced surveillance program. Such a program involves regular sharing of safety information that might not otherwise meet the threshold for reporting to the competent authority. This will allow the MHRA to have a more in depth look at the performance of the test in use and if this highlights any regulatory or safety issues then they will consider further action.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3344 HL3345 HL3346 HL3347 HL3348 question first answered 16/12/2014 14:44:43 answering member 2000 label Biography information for Earl Howe
tabling member	4286 label Biography information for Lord Mendelsohn

167243

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	23andMe
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether the US Food and Drug Administration provided the Medicines and Healthcare Products Regulatory Agency with information about the status of its ban on 23andMe; and whether it was likely to change its position.
tabling member printed	Lord Mendelsohn
uin	HL3344
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>Products used in direct-to-consumer testing services providing health-related information are regulated as <em>in vitro</em> diagnostic medical devices and are subject to European Union legislation that sets out minimum standards of safety and quality. The testing service itself is not subject to this legislation, only the products.</p><p> </p><p> </p><p> </p><p>Manufacturers of <em>in vitro</em> diagnostic medical devices are required to register with the competent authority in the country where they are placing the device on the market. In the United Kingdom this is the Medicines and Healthcare products Regulatory Agency (MHRA). In this registration a manufacturer declares that their devices are safe and meet all of the relevant requirements of the legislation including having evidence to support their performance claims. For some higher risk devices a manufacturer has to have its product checked before it is placed on the market. Such checks are undertaken by third-party conformity assessment bodies called notified bodies.</p><p> </p><p> </p><p> </p><p>The role of the MHRA is to ensure that all medical devices placed on the UK market are compliant with the relevant legislation and to enforce this legislation on behalf of the Secretary of State. The MHRA fulfils this role by monitoring notified bodies (for higher risk devices) and operating the UK medical device vigilance system, which involves assessing and responding to safety concerns involving devices.</p><p> </p><p> </p><p> </p><p>The MHRA does not have a role in assessing the additional costs or benefits of devices to the National Health Service and so has not done so in the case of the service offered by 23andMe.</p><p> </p><p> </p><p> </p><p>Furthermore, under existing EU legislation, testing services are regulated in the country where the test is being performed. The tests offered by 23andMe are performed in laboratories that are based in the United States of America and as such are covered by US legislation.</p><p> </p><p> </p><p> </p><p>The Government has advised that no test will be 100% reliable, that 23andMe should be used with caution and that the information provided by 23andMe should not lead consumers to make any changes of medical significance, such as changes to medication, without first consulting their healthcare professional. If consumers need more information about the conditions listed in their results then they can visit the NHS Choices website for more information.</p><p> </p><p> </p><p> </p><p>The MHRA discussed the 23andMe Personal Genome Service with the US Food and Drug Administration (FDA) and shared information under the confidentiality commitment that is in place between the two agencies.</p><p> </p><p> </p><p> </p><p>The MHRA also held discussions with 23andMe prior to them launching their product in the UK. In those discussions, 23andMe explained that the product being offered in the UK is different to their US product in that many of the drug responses, inherited conditions and genetic health risks that were of concern to the FDA have been removed. 23andMe also presented results of surveys with UK-based consumers of their existing service that demonstrated that 4% of people had a specific conversation with their general practitioner (GP) as a result of their test results but it is not known how many GP visits led to National Health Service treatment.</p><p> </p><p> </p><p> </p><p>In the context of those discussions, the MHRA also agreed with 23andMe that they would take part in an enhanced surveillance program. Such a program involves regular sharing of safety information that might not otherwise meet the threshold for reporting to the competent authority. This will allow the MHRA to have a more in depth look at the performance of the test in use and if this highlights any regulatory or safety issues then they will consider further action.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3343 HL3345 HL3346 HL3347 HL3348 question first answered 16/12/2014 14:44:44 answering member 2000 label Biography information for Earl Howe
tabling member	4286 label Biography information for Lord Mendelsohn

167244

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	23andMe
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what advice they will give to patients about the reliability of information received from tests by 23andMe; and whether any indication of a health condition should lead patients to seek National Health Service treatment.
tabling member printed	Lord Mendelsohn
uin	HL3345
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>Products used in direct-to-consumer testing services providing health-related information are regulated as <em>in vitro</em> diagnostic medical devices and are subject to European Union legislation that sets out minimum standards of safety and quality. The testing service itself is not subject to this legislation, only the products.</p><p> </p><p> </p><p> </p><p>Manufacturers of <em>in vitro</em> diagnostic medical devices are required to register with the competent authority in the country where they are placing the device on the market. In the United Kingdom this is the Medicines and Healthcare products Regulatory Agency (MHRA). In this registration a manufacturer declares that their devices are safe and meet all of the relevant requirements of the legislation including having evidence to support their performance claims. For some higher risk devices a manufacturer has to have its product checked before it is placed on the market. Such checks are undertaken by third-party conformity assessment bodies called notified bodies.</p><p> </p><p> </p><p> </p><p>The role of the MHRA is to ensure that all medical devices placed on the UK market are compliant with the relevant legislation and to enforce this legislation on behalf of the Secretary of State. The MHRA fulfils this role by monitoring notified bodies (for higher risk devices) and operating the UK medical device vigilance system, which involves assessing and responding to safety concerns involving devices.</p><p> </p><p> </p><p> </p><p>The MHRA does not have a role in assessing the additional costs or benefits of devices to the National Health Service and so has not done so in the case of the service offered by 23andMe.</p><p> </p><p> </p><p> </p><p>Furthermore, under existing EU legislation, testing services are regulated in the country where the test is being performed. The tests offered by 23andMe are performed in laboratories that are based in the United States of America and as such are covered by US legislation.</p><p> </p><p> </p><p> </p><p>The Government has advised that no test will be 100% reliable, that 23andMe should be used with caution and that the information provided by 23andMe should not lead consumers to make any changes of medical significance, such as changes to medication, without first consulting their healthcare professional. If consumers need more information about the conditions listed in their results then they can visit the NHS Choices website for more information.</p><p> </p><p> </p><p> </p><p>The MHRA discussed the 23andMe Personal Genome Service with the US Food and Drug Administration (FDA) and shared information under the confidentiality commitment that is in place between the two agencies.</p><p> </p><p> </p><p> </p><p>The MHRA also held discussions with 23andMe prior to them launching their product in the UK. In those discussions, 23andMe explained that the product being offered in the UK is different to their US product in that many of the drug responses, inherited conditions and genetic health risks that were of concern to the FDA have been removed. 23andMe also presented results of surveys with UK-based consumers of their existing service that demonstrated that 4% of people had a specific conversation with their general practitioner (GP) as a result of their test results but it is not known how many GP visits led to National Health Service treatment.</p><p> </p><p> </p><p> </p><p>In the context of those discussions, the MHRA also agreed with 23andMe that they would take part in an enhanced surveillance program. Such a program involves regular sharing of safety information that might not otherwise meet the threshold for reporting to the competent authority. This will allow the MHRA to have a more in depth look at the performance of the test in use and if this highlights any regulatory or safety issues then they will consider further action.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3343 HL3344 HL3346 HL3347 HL3348 question first answered 16/12/2014 14:44:44 answering member 2000 label Biography information for Earl Howe
tabling member	4286 label Biography information for Lord Mendelsohn

167245

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	DNA: Screening
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what are the minimum standards required for a personal genome service to be approved by the Medicines and Healthcare Products Regulatory Agency.
tabling member printed	Lord Mendelsohn
uin	HL3346
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>Products used in direct-to-consumer testing services providing health-related information are regulated as <em>in vitro</em> diagnostic medical devices and are subject to European Union legislation that sets out minimum standards of safety and quality. The testing service itself is not subject to this legislation, only the products.</p><p> </p><p> </p><p> </p><p>Manufacturers of <em>in vitro</em> diagnostic medical devices are required to register with the competent authority in the country where they are placing the device on the market. In the United Kingdom this is the Medicines and Healthcare products Regulatory Agency (MHRA). In this registration a manufacturer declares that their devices are safe and meet all of the relevant requirements of the legislation including having evidence to support their performance claims. For some higher risk devices a manufacturer has to have its product checked before it is placed on the market. Such checks are undertaken by third-party conformity assessment bodies called notified bodies.</p><p> </p><p> </p><p> </p><p>The role of the MHRA is to ensure that all medical devices placed on the UK market are compliant with the relevant legislation and to enforce this legislation on behalf of the Secretary of State. The MHRA fulfils this role by monitoring notified bodies (for higher risk devices) and operating the UK medical device vigilance system, which involves assessing and responding to safety concerns involving devices.</p><p> </p><p> </p><p> </p><p>The MHRA does not have a role in assessing the additional costs or benefits of devices to the National Health Service and so has not done so in the case of the service offered by 23andMe.</p><p> </p><p> </p><p> </p><p>Furthermore, under existing EU legislation, testing services are regulated in the country where the test is being performed. The tests offered by 23andMe are performed in laboratories that are based in the United States of America and as such are covered by US legislation.</p><p> </p><p> </p><p> </p><p>The Government has advised that no test will be 100% reliable, that 23andMe should be used with caution and that the information provided by 23andMe should not lead consumers to make any changes of medical significance, such as changes to medication, without first consulting their healthcare professional. If consumers need more information about the conditions listed in their results then they can visit the NHS Choices website for more information.</p><p> </p><p> </p><p> </p><p>The MHRA discussed the 23andMe Personal Genome Service with the US Food and Drug Administration (FDA) and shared information under the confidentiality commitment that is in place between the two agencies.</p><p> </p><p> </p><p> </p><p>The MHRA also held discussions with 23andMe prior to them launching their product in the UK. In those discussions, 23andMe explained that the product being offered in the UK is different to their US product in that many of the drug responses, inherited conditions and genetic health risks that were of concern to the FDA have been removed. 23andMe also presented results of surveys with UK-based consumers of their existing service that demonstrated that 4% of people had a specific conversation with their general practitioner (GP) as a result of their test results but it is not known how many GP visits led to National Health Service treatment.</p><p> </p><p> </p><p> </p><p>In the context of those discussions, the MHRA also agreed with 23andMe that they would take part in an enhanced surveillance program. Such a program involves regular sharing of safety information that might not otherwise meet the threshold for reporting to the competent authority. This will allow the MHRA to have a more in depth look at the performance of the test in use and if this highlights any regulatory or safety issues then they will consider further action.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3343 HL3344 HL3345 HL3347 HL3348 question first answered 16/12/2014 14:44:44 answering member 2000 label Biography information for Earl Howe
tabling member	4286 label Biography information for Lord Mendelsohn

167246

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medicines and Healthcare products Regulatory Agency
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what is the difference in the reliance that individuals can place on what they learn from a medical product regulated by the Medicines and Healthcare Products Regulatory Agency compared to an information product.
tabling member printed	Lord Mendelsohn
uin	HL3347
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>Products used in direct-to-consumer testing services providing health-related information are regulated as <em>in vitro</em> diagnostic medical devices and are subject to European Union legislation that sets out minimum standards of safety and quality. The testing service itself is not subject to this legislation, only the products.</p><p> </p><p> </p><p> </p><p>Manufacturers of <em>in vitro</em> diagnostic medical devices are required to register with the competent authority in the country where they are placing the device on the market. In the United Kingdom this is the Medicines and Healthcare products Regulatory Agency (MHRA). In this registration a manufacturer declares that their devices are safe and meet all of the relevant requirements of the legislation including having evidence to support their performance claims. For some higher risk devices a manufacturer has to have its product checked before it is placed on the market. Such checks are undertaken by third-party conformity assessment bodies called notified bodies.</p><p> </p><p> </p><p> </p><p>The role of the MHRA is to ensure that all medical devices placed on the UK market are compliant with the relevant legislation and to enforce this legislation on behalf of the Secretary of State. The MHRA fulfils this role by monitoring notified bodies (for higher risk devices) and operating the UK medical device vigilance system, which involves assessing and responding to safety concerns involving devices.</p><p> </p><p> </p><p> </p><p>The MHRA does not have a role in assessing the additional costs or benefits of devices to the National Health Service and so has not done so in the case of the service offered by 23andMe.</p><p> </p><p> </p><p> </p><p>Furthermore, under existing EU legislation, testing services are regulated in the country where the test is being performed. The tests offered by 23andMe are performed in laboratories that are based in the United States of America and as such are covered by US legislation.</p><p> </p><p> </p><p> </p><p>The Government has advised that no test will be 100% reliable, that 23andMe should be used with caution and that the information provided by 23andMe should not lead consumers to make any changes of medical significance, such as changes to medication, without first consulting their healthcare professional. If consumers need more information about the conditions listed in their results then they can visit the NHS Choices website for more information.</p><p> </p><p> </p><p> </p><p>The MHRA discussed the 23andMe Personal Genome Service with the US Food and Drug Administration (FDA) and shared information under the confidentiality commitment that is in place between the two agencies.</p><p> </p><p> </p><p> </p><p>The MHRA also held discussions with 23andMe prior to them launching their product in the UK. In those discussions, 23andMe explained that the product being offered in the UK is different to their US product in that many of the drug responses, inherited conditions and genetic health risks that were of concern to the FDA have been removed. 23andMe also presented results of surveys with UK-based consumers of their existing service that demonstrated that 4% of people had a specific conversation with their general practitioner (GP) as a result of their test results but it is not known how many GP visits led to National Health Service treatment.</p><p> </p><p> </p><p> </p><p>In the context of those discussions, the MHRA also agreed with 23andMe that they would take part in an enhanced surveillance program. Such a program involves regular sharing of safety information that might not otherwise meet the threshold for reporting to the competent authority. This will allow the MHRA to have a more in depth look at the performance of the test in use and if this highlights any regulatory or safety issues then they will consider further action.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3343 HL3344 HL3345 HL3346 HL3348 question first answered 16/12/2014 14:44:44 answering member 2000 label Biography information for Earl Howe
tabling member	4286 label Biography information for Lord Mendelsohn

167247

registered interest
date	02/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	23andMe
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment the Medicines and Healthcare Products Regulatory Agency has made of the additional costs or benefits to the National Health Service of the use of 23andMe.
tabling member printed	Lord Mendelsohn
uin	HL3348
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>Products used in direct-to-consumer testing services providing health-related information are regulated as <em>in vitro</em> diagnostic medical devices and are subject to European Union legislation that sets out minimum standards of safety and quality. The testing service itself is not subject to this legislation, only the products.</p><p> </p><p> </p><p> </p><p>Manufacturers of <em>in vitro</em> diagnostic medical devices are required to register with the competent authority in the country where they are placing the device on the market. In the United Kingdom this is the Medicines and Healthcare products Regulatory Agency (MHRA). In this registration a manufacturer declares that their devices are safe and meet all of the relevant requirements of the legislation including having evidence to support their performance claims. For some higher risk devices a manufacturer has to have its product checked before it is placed on the market. Such checks are undertaken by third-party conformity assessment bodies called notified bodies.</p><p> </p><p> </p><p> </p><p>The role of the MHRA is to ensure that all medical devices placed on the UK market are compliant with the relevant legislation and to enforce this legislation on behalf of the Secretary of State. The MHRA fulfils this role by monitoring notified bodies (for higher risk devices) and operating the UK medical device vigilance system, which involves assessing and responding to safety concerns involving devices.</p><p> </p><p> </p><p> </p><p>The MHRA does not have a role in assessing the additional costs or benefits of devices to the National Health Service and so has not done so in the case of the service offered by 23andMe.</p><p> </p><p> </p><p> </p><p>Furthermore, under existing EU legislation, testing services are regulated in the country where the test is being performed. The tests offered by 23andMe are performed in laboratories that are based in the United States of America and as such are covered by US legislation.</p><p> </p><p> </p><p> </p><p>The Government has advised that no test will be 100% reliable, that 23andMe should be used with caution and that the information provided by 23andMe should not lead consumers to make any changes of medical significance, such as changes to medication, without first consulting their healthcare professional. If consumers need more information about the conditions listed in their results then they can visit the NHS Choices website for more information.</p><p> </p><p> </p><p> </p><p>The MHRA discussed the 23andMe Personal Genome Service with the US Food and Drug Administration (FDA) and shared information under the confidentiality commitment that is in place between the two agencies.</p><p> </p><p> </p><p> </p><p>The MHRA also held discussions with 23andMe prior to them launching their product in the UK. In those discussions, 23andMe explained that the product being offered in the UK is different to their US product in that many of the drug responses, inherited conditions and genetic health risks that were of concern to the FDA have been removed. 23andMe also presented results of surveys with UK-based consumers of their existing service that demonstrated that 4% of people had a specific conversation with their general practitioner (GP) as a result of their test results but it is not known how many GP visits led to National Health Service treatment.</p><p> </p><p> </p><p> </p><p>In the context of those discussions, the MHRA also agreed with 23andMe that they would take part in an enhanced surveillance program. Such a program involves regular sharing of safety information that might not otherwise meet the threshold for reporting to the competent authority. This will allow the MHRA to have a more in depth look at the performance of the test in use and if this highlights any regulatory or safety issues then they will consider further action.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3343 HL3344 HL3345 HL3346 HL3347 question first answered 16/12/2014 14:44:43 answering member 2000 label Biography information for Earl Howe
tabling member	4286 label Biography information for Lord Mendelsohn

166202

registered interest
date	26/11/2014
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	Islamic State
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how much they estimate IS to have received in kidnap ransoms; and what assessment they have made of the reported Iraqi intelligence estimates that they have received $200 million.
tabling member printed	Lord Mendelsohn
uin	HL3186
answer	answer is ministerial correction date of answer 11/12/2014 answer text <p>There is considerable speculation over how much the Islamic State of Iraq and the Levant (ISIL) and other terrorist groups have secured from kidnapping for ransom. In October 2014 the UN Al Qaeda Sanctions Monitoring Team estimated that ISIL had received between US$35 and US$45 million in ransom payments in the preceding twelve months.</p> answering member printed Baroness Anelay of St Johns question first answered 11/12/2014 12:48:40 answering member 3474 label Biography information for Baroness Anelay of St Johns
tabling member	4286 label Biography information for Lord Mendelsohn

166203

registered interest
date	26/11/2014
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	Islamic State
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government which governments they are aware of which have paid ransoms to IS; and what discussions they have had with them.
tabling member printed	Lord Mendelsohn
uin	HL3187
answer	answer is ministerial correction date of answer 04/12/2014 answer text <p>The UN Al Qaeda Sanctions regime sets out the international legal framework. It makes clear that ransom payments to terrorist organisations are illegal. All UN Member States are bound by this. We are unable to comment on reports of ransom payments by other countries. <br><br>The UK policy position is clear. We do not pay ransoms or make any other substantive concessions to terrorists. Ransom payments strengthen terrorist groups and encourage them to carry out further kidnaps. This is why the UK has also led the drive to secure agreement on the principle of not paying ransoms. Under UK Presidency in 2013 the G8 made an unequivocal commitment to reject ransom payments to terrorists. The UK also secured the first standalone UN Security Council Resolution (UNSCR) on tackling terrorist ransom payments, which was unanimously adopted in January 2014, as UNSCR 2133.</p> answering member printed Baroness Anelay of St Johns question first answered 04/12/2014 15:52:59 answering member 3474 label Biography information for Baroness Anelay of St Johns
tabling member	4286 label Biography information for Lord Mendelsohn

166204

registered interest
date	26/11/2014
answering body	HM Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Financial Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they have any plans to introduce legislation obliging financial companies to protect against cyberbreaches, money laundering and fraud.
tabling member printed	Lord Mendelsohn
uin	HL3188
answer	answer is ministerial correction date of answer 09/12/2014 answer text <p>The UK already has a comprehensive anti-money laundering and counter financing of terrorism regime. The international money laundering standards set by the Financial Action Task Force form the basis of EU legislation, which is incorporated into various pieces of UK law, predominantly the Money Laundering Regulations (2007) and the Proceeds of Crime Act (2002), both of which apply to financial institutions.</p><p> </p><p> </p><p> </p><p>The UK Government has no plans to introduce legislation obliging financial companies to protect against fraud. The Financial Conduct Authority (FCA), which regulates most financial institutions, expects firms within its supervisory remit to establish, implement and maintain adequate policies and procedures to reduce the risk that they may be used for financial crime. This includes money laundering, anti-bribery and corruption, and fraud.</p><p> </p><p> </p><p> </p><p>The Government works very closely with the financial sector through such initiatives as the CISP (Cyber Security Information Sharing Partnership) and CERT-UK (the UK’s national Computer Emergency Response Team), and has participated in cyber security exercises with the sector to test defences, such as the Waking Shark II exercise held earlier this year. In addition, the Treasury is working with the relevant Government agencies, the Bank of England (including the Prudential Regulation Authority) and the FCA to respond to the Financial Policy Committee’s recommendation to work with core parts of the UK financial sector to put in place a programme of work to improve and test resilience to cyber attack.</p><p> </p> answering member printed Lord Deighton question first answered 09/12/2014 17:50:42 answering member 4262 label Biography information for Lord Deighton
tabling member	4286 label Biography information for Lord Mendelsohn

166086

registered interest
date	25/11/2014
answering body	HM Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Financial Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what plans they have to review the fund management industry in the light of the finding by the Financial Services Consumer Panel that it has "underlying structural deficiencies" which are working to the detriment of retail investors.
tabling member printed	Lord Mendelsohn
uin	HL3144
answer	answer is ministerial correction date of answer 09/12/2014 answer text <p>The government is committed to ensuring that customers are treated fairly when they make investment decisions and are able to get the best outcomes from their investments. Ensuring that customers can easily understand and compare products is an important part of this. The Government noted the Financial Services Consumer Panel’s contribution to the debate on these issues, including introducing a single figure for costs, and will consider the recommendations made.</p><p> </p> answering member printed Lord Deighton grouped question UIN HL3148 question first answered 09/12/2014 17:24:59 answering member 4262 label Biography information for Lord Deighton
tabling member	4286 label Biography information for Lord Mendelsohn